Indication
Anti-acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis
Anti-acetylcholine receptor antibody positive generalized myasthenia gravis is a chronic autoimmune disorder affecting the neuromuscular junction across the peripheral nervous and muscular systems. Read more about Anti-acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis
7 drugs 5 manufacturers
Drugs that treat it
Common Anti-acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis therapies.
ULTOMIRIS (ravulizumab-cwvz)
UPLIZNA (inebilizumab-cdon)
RYSTIGGO (rozanolixizumab-noli)
ZILBRYSQ (zilucoplan sodium)
UPLIZNA (inebilizumab-cdon)
IMAAVY (nipocalimab-aahu)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnti-acetylcholine receptor antibody positive generalized myasthenia gravis is a chronic autoimmune disorder affecting the neuromuscular junction across the peripheral nervous and muscular systems.
It is pathophysiologically defined by circulating pathogenic autoantibodies directed against nicotinic acetylcholine receptors on the postsynaptic muscle endplate, precipitating receptor blockade, internalization, and complement-mediated destruction of the neuromuscular junction.
Clinically, it presents with fluctuating, fatigable skeletal muscle weakness extending beyond the ocular musculature to involve bulbar, limb, neck, and respiratory muscles, with symptoms typically worsening after sustained exertion.
- nih.gov
Anti-acetylcholine receptor antibody positive generalized myasthenia gravis is a chronic autoimmune disorder affecting the neuromuscular junction across the peripheral nervous and muscular systems
- nih.gov
Anti-acetylcholine receptor antibody positive generalized myasthenia gravis is a chronic autoimmune disorder affecting the neuromuscular junction across the peripheral nervous and muscular systems It is pathophysiologically defined by circulating pathogenic autoantibodies directed against nicotinic acetylcholine receptors on the postsynaptic muscle endplate, precipitating receptor blockade, internalization, and complement-mediated destruction of the neuromuscular junction
- expertperspectives.com
It is pathophysiologically defined by circulating pathogenic autoantibodies directed against nicotinic acetylcholine receptors on the postsynaptic muscle endplate, precipitating receptor blockade, internalization, and complement-mediated destruction of the neuromuscular junction Clinically, it presents with fluctuating, fatigable skeletal muscle weakness extending beyond the ocular musculature to involve bulbar, limb, neck, and respiratory muscles, with symptoms typically worsening after sustain...
- nih.gov
Clinically, it presents with fluctuating, fatigable skeletal muscle weakness extending beyond the ocular musculature to involve bulbar, limb, neck, and respiratory muscles, with symptoms typically worsening after sustained exertion
- nih.gov
Clinically, it presents with fluctuating, fatigable skeletal muscle weakness extending beyond the ocular musculature to involve bulbar, limb, neck, and respiratory muscles, with symptoms typically worsening after sustained exertion
- myastheniagravisnews.com
Clinically, it presents with fluctuating, fatigable skeletal muscle weakness extending beyond the ocular musculature to involve bulbar, limb, neck, and respiratory muscles, with symptoms typically worsening after sustained exertion
Personalize your experience
Follow Anti-acetylcholine receptor (AChR) antibody positive generalized myasthenia gravis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.